Nigeria Pilot • 2026

A digital pharmacist
in every pocket.

Closing the medication safety gap across Africa with AI that verifies authenticity, speaks local languages, and works offline.

40 million smartphone users targeted in Phase 1

9:41 100% 􀛨
RXASSIST
Good morning, Amina
SCAN MEDICATION
Amoxicillin 500mg
VERIFIED
Rx
Trust Score: 98.4
Manufacturer verified
TODAY'S GUIDANCE
Take with food. Complete full 7-day course to prevent resistance.
1.2m scans today
98.7% authenticity rate
THE REALITY

The silent crisis
no one is talking about.

In Sub-Saharan Africa, the simple act of taking medication carries unacceptable risk.

70%
of medications are purchased
without any professional consultation
Patients rely on informal vendors with limited clinical training.
1 in 6
drugs in circulation are counterfeit
These "silent killers" fuel antimicrobial resistance and preventable deaths.
1:10,000
pharmacist-to-patient ratio
in rural Nigeria
A human-resource gap that forces dangerous self-medication culture.

This is not a supply problem. It is a trust and guidance problem. RxAssist exists to solve it at population scale.

THE SOLUTION

RxAssist.
AI that protects.
Guidance that understands.

A 24/7 digital pharmacist that combines computer vision for counterfeit detection with intelligent, multilingual clinical support — designed from the ground up for low-connectivity environments.

Targeting UN SDG 3 Good Health & Well-being

Counterfeit Shield

High-resolution smartphone scanning analyzes holograms, serial numbers, and packaging security features against a proprietary manufacturer database. Instant Trust Score in seconds.

Voice of the Patient

Clinical guidance delivered in Yoruba, Hausa, Igbo, Pidgin, and English. Complex dosage instructions and side-effect warnings become clear in the patient’s mother tongue.

Resilient by Design

Sync-and-Save architecture. Core databases and adherence schedules remain fully functional even when cellular data is unavailable — critical for rural communities.

Adherence Guardian

AI-driven reminders, drug-drug and drug-food interaction alerts, and intelligent nudges to complete antibiotic courses — protecting both the individual and public health from resistance.

MEASURABLE OUTCOMES

Built for real impact.
Not vanity metrics.

ADHERENCE
5075
Regional average → Target adherence rate
Through personalized, intelligent reminders
ERROR REDUCTION
40%
Reduction in drug interaction errors
Powered by real-time clinical decision support
SCALE
40M
Underserved smartphone users in initial target
Nigeria pilot → West Africa → Continent
AMR COMBAT
100%
Course completion education
Protecting the effectiveness of life-saving antibiotics
EXECUTION

Roadmap to 2030

A deliberate, phased approach to building sustainable pharmaceutical infrastructure across the continent.

PHASE 01 • 2026–2027

Nigeria Pilot

Launch in Lagos urban hubs and select rural clusters in Northern Nigeria. Focus on 40 million smartphone users. Deep NLP training for major local languages.

Target: 250,000 active users in Year 1
PHASE 02 • 2028–2029

West African Expansion

Scale to Ghana and Côte d’Ivoire. Adapt NLP models for additional dialects. Strengthen B2B partnerships with regional pharmacy chains and health systems.

Target: 2.5 million users across three countries
PHASE 03 • 2030+

Continental Integration

Pan-African rollout. Capture meaningful share of the $65 billion African pharmaceutical market. Become the default layer of medication safety infrastructure.

Target: 25+ million users
THE VISIONARY

Built by someone who cares deeply about the outcome.

NF
FOUNDER

Nathaniel Friday

Founder & Visionary

Nathaniel founded RxAssist to close one of healthcare’s most dangerous gaps: the moment between receiving a prescription and safely completing treatment. He believes frontier AI, when built with cultural intelligence and radical accessibility, can protect millions of lives across the continent.
COMING SOON

Be among the first.

The Nigeria pilot launches in late 2026. Early access is limited to patients, healthcare professionals, and partners who want to shape the future of medication safety in Africa.

We respect your inbox. Unsubscribe anytime. Pilot spots are extremely limited.